Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients

Launched by MOSTAFA BAHAA · May 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how effective two medications—Metformin and Febuxostat—are in treating gout in obese patients who do not have diabetes. Gout is a painful condition caused by high levels of uric acid in the blood, which can form crystals in the joints, leading to inflammation and discomfort. The trial aims to find out which medication is better at lowering uric acid levels and preventing gout attacks in people who are overweight or obese, as managing these levels is crucial for treatment.

To participate in this study, individuals need to be between the ages of 18 and 75, diagnosed with gout, and have a body mass index (BMI) of 30 or higher, indicating obesity. However, those with diabetes, certain other health conditions, or who are pregnant or breastfeeding cannot take part. Participants will be monitored for how well the medications work and how they affect their uric acid levels, helping researchers understand the best options for managing gout in obese patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males or females aged \< 18 years.
• • All patients are diagnosed to have gout with serum uric acid \< 7 mg/dl.
• • All patients are diagnosed to have obesity with body mass index (BMI) ≥ 30 kg/m2.
• Exclusion Criteria:
• • The presence of any type of diabetes mellitus.
• • Patients with drug-induced hyperuriceamia (those taking anti-TB agents, low dose aspirin, cytotoxic chemotherapy, diuretics, immunosuppressants, fructose, lactate infusion, testosterone or xylitol).
• • Non-obese patients with BMI \>30 kg/m2.
• • Pregnant or lactating women.